Article PDF
References
Deckert T, Hansen B, Lauritzen T, Sandahl Christiansen J (1980) Subcutaneous degradation of insulin. Diabetologia 21: 161–162 (Letter)
Stevenson RW, Tsakok TI, Parsons JA (1980) Matched glucose responses to insulin administered subcutaneously and intravenously. Evidence for subcutaneous inactivation of insulin. Diabetologia 18:423–426
Berger M, Halban PA, Muller WA, Offord RE, Renold AE, Vranic M (1978) Mobilization of subcutaneously injected tritiated insulin in rats: effects of muscular exercise. Diabetologia 15:133–140
Berger M, Halban PA, Girardier L, Seydoux J, Offord RE, Renold AE (1979) Absorption kinetics of subcutaneously injected insulin. Evidence for degradation at the injection site. Diabetologia 17: 97–99
Pickup JC, Home PD, Bilous RW, Keen H, Alberti KGMM (1981) Management of severely brittle diabetes by continous subcutaneous and intramuscular insulin infusions: evidence for a defect in insulin absorption. Br Med J 282: 347–350
Dandona P, Foster M, Healey F, Greenbury E, Beckett AG (1978) Low-dose insulin infusions in diabetic patients with high insulin requirements. Lancet 2: 283–285
Paulsen EP, Courtney III JW, Duckworth WC (1979) Insulin resistance caused by massive degradation of subcutaneous insulin. Diabetes 28: 640–645
Pickup JC, Bilous RW, Keen H (1981) Aprotinin and insulin resistance. Lancet 2: 93–94 (Letter)
Freidenberg GR, White N, Cataland S, O'Dorisio TM, Sotos JF, Santiago JV (1980) Diabetes responsive to intravenous but not subcutaneous insulin: effectiveness of aprotinin. N Engl J Med 305: 363–368
Berger M, Cuppers HJ, Halban PA, Offord RE (1980) The effect of aprotinin on the absorption of subcutaneously injected regular insulin in normal subjects. Diabetes 29: 81–83
McElduff A, Eastman CJ, Haynes SP, Bowen KM (1980) Apparent insulin resistance due to abnormal enzymatic insulin degradation: a new mechanism for insulin resistance. Aust NZ J Med 10: 56–61
Muller WA, Taillens C, Léreret S, Berger M, Pillippe J, Halban PA, Offord RE (1980) Resistance against subcutaneous insulin successfully managed with aprotinin. Lancet 1: 1245–1246 (Letter)
Parsons JA, Rafferty B, Stevenson RW, Zanelli JM (1979) Evidence that protease inhibitors reduce the degradation of parathyroid hormone and calcitonin injected subcutaneously. Br J Pharmacol 66: 25–32
Reeve J, Meunier PJ, Parsons JA, Bernat M, Bijvoet OLM, Courpron P, Edouard C, Klenerman L, Neer RM, Renier JC, Slovik D, Vismans FJFE, Potts Jr JT (1980) Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. Br Med J 280: 1340–1352
Podbesek RD, Stevenson RW, Zanelli GD, Edouard C, Meunier PJ, Reeve J, Parsons JA (1981) Treatment with human parathyroid hormone fragment (hPTH 1-34) stimulates bone formation and intestinal calcium absorption in the greyhound: comparison with data from the osteoporosis trial. In: Cohn DV (ed) Hormonal control of calcium metabolism. Proceedings of the 7th International Conference on Calcium Regulating Hormones, Colorado, September 1980. Excerpta Medica, Amsterdam, pp 118–123
Hoare SM, Offord RE (1981) Inhibition of subcutaneous 3H-insulin degradation by glutathione analogues, Trasylol derivatives, and small peptide hormones. Diabetologia 21: 508 (Abstract)
Lauritzen T, Faber OK, Binder C (1979) Variation in 125I-insulin absorption and blood glucose concentration. Diabetologia 17: 291–295
Williams G, Clark AJL, Cook E, Bowcock S, Pickup JC, Keen H (1981) Local changes in subcutaneous blood flow around insulin injection sites measured by photoelectric plethysmography. Diabetologia 21: 516 (Abstract)
Lauritzen T, Binder C, Faber OK (1980) Importance of insulin absorption, subcutaneous blood flow, and residual beta-cell function in insulin therapy. Acta Paediatr Scand (Suppl) 283: 81–85
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Stevenson, R.W. Subcutaneous degradation of insulin. Diabetologia 22, 221–223 (1982). https://doi.org/10.1007/BF00283760
Issue Date:
DOI: https://doi.org/10.1007/BF00283760